Literature DB >> 18789101

Multiple basal cell carcinomas in xeroderma pigmentosum treated with imiquimod 5% cream.

Amit Kumar Malhotra1, Somesh Gupta, Binod K Khaitan, Kaushal K Verma.   

Abstract

We report successful treatment of multiple basal cell carcinomas with imiquimod 5% cream in a 16-year-old boy with xeroderma pigmentosum and review the possibility of prophylactic role of imiquimod in the disease. Imiquimod cream was applied uniformly over all the basal cell carcinoma lesions and background pigmented skin, once at bedtime on every alternate day for 12 weeks. Besides the basal cell carcinomas, the background hyperpigmentation and keratotic papules also cleared, and the skin texture improved. The lesions did not recur at the treated sites during the follow up of 1 year.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789101     DOI: 10.1111/j.1525-1470.2008.00727.x

Source DB:  PubMed          Journal:  Pediatr Dermatol        ISSN: 0736-8046            Impact factor:   1.588


  4 in total

Review 1.  Xeroderma pigmentosum: overview of pharmacology and novel therapeutic strategies for neurological symptoms.

Authors:  Rosella Abeti; Anna Zeitlberger; Colm Peelo; Hiva Fassihi; Robert P E Sarkany; Alan R Lehmann; Paola Giunti
Journal:  Br J Pharmacol       Date:  2019-01-23       Impact factor: 8.739

Review 2.  Therapeutics of xeroderma pigmentosum: A PRISMA-compliant systematic review.

Authors:  Fernando Antônio Gomes de Andrade; Claudio Eduardo de Oliveira Cavalcanti; Felipe Contoli Isoldi; Lydia Masako Ferreira
Journal:  Indian J Dermatol Venereol Leprol       Date:  2021 Mar-Apr       Impact factor: 2.545

3.  Nonsyndromic Multiple Basal Cell Carcinomas.

Authors:  Dong Hwi Kim; Hyo Sun Ko; Young Joon Jun
Journal:  Arch Craniofac Surg       Date:  2017-09-26

Review 4.  Current Therapeutic Strategies of Xeroderma Pigmentosum.

Authors:  Mozammel Hossain; Ashraful Hasan; Mohammad Mahfuz Ali Khan Shawan; Subrata Banik; Iffat Jahan
Journal:  Indian J Dermatol       Date:  2021 Nov-Dec       Impact factor: 1.494

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.